Patents by Inventor Carl W. Gilbert
Carl W. Gilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7449315Abstract: Energy-reversible acyl conjugates, intermediates, and related compositions are disclosed.Type: GrantFiled: March 30, 2007Date of Patent: November 11, 2008Assignee: Cryolife, Inc.Inventors: Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
-
Patent number: 7157458Abstract: Energy-reversible acyl conjugates, intermediates, and related compositions are disclosed.Type: GrantFiled: January 31, 2002Date of Patent: January 2, 2007Assignee: Cryolife, Inc.Inventors: Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
-
Patent number: 6774116Abstract: A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety's electric properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biologically active molecule moiety and the cinnamic acid backbone. The biologically active molecule can be any biologically active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, campotothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug composition can be modified to add a carrier moiety on the prodrug composition for targeting or to facilitate uptake of the drug. The prodrug compositions can be activated with an energy source to release the drug at the desired site.Type: GrantFiled: January 31, 2002Date of Patent: August 10, 2004Assignee: Cryolife, Inc.Inventors: Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
-
Publication number: 20020187992Abstract: A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically donating or electronically withdrawing groups to modify the cinnamate moiety's electric properties as well as photo reactivities for the purpose of achieving a proper hydrolysis rate of the acyl bond between the biologically active molecule moiety and the cinnamic acid backbone. The biologically active molecule can be any biologically active agent or diagnostic, for example, a chemotherapeutic such as a paclitaxel, campotothecin, doxorubicin, amethopterin, etoposide, or fluconazole. The prodrug composition can be modified to add a carrier moiety on the prodrug composition for targeting or to facilitate uptake of the drug. The prodrug compositions can be activated with an energy source to release the drug at the desired site.Type: ApplicationFiled: January 31, 2002Publication date: December 12, 2002Inventors: Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
-
Publication number: 20020187993Abstract: Energy-reversible acyl conjugates, intermediates, and related compositions are disclosed.Type: ApplicationFiled: January 31, 2002Publication date: December 12, 2002Inventors: Carl W. Gilbert, Eleanor B. McGowan, Kirby S. Black, T. Gregory P. Harper
-
Patent number: 6042822Abstract: Compositions containing alpha interferon conjugated to a substantially non-antigenic polymer are disclosed in which at least about 30% of the conjugates include covalent attachment of the alpha interferon to the substantially non-antigenic polymer at a histidine. Also disclosed is a process for preparing the conjugates. The process includes contacting an alpha interferon with a succinimidyl carbonate-activated substantially non-antigenic polymer at a pH which is sufficient to facilitate covalent attachment of the polymer on a histidine of the alpha interferon.Type: GrantFiled: April 6, 1999Date of Patent: March 28, 2000Assignee: Enzon, Inc.Inventors: Carl W. Gilbert, Myung-ok Park-Cho
-
Patent number: 5981709Abstract: A process for preparing .alpha.-interferon-polymer conjugates having high levels of retained interferon activity and relatively long circulating lives in vivo is disclosed. The process includes forming substantially non-antigenic .alpha.-interferon-polymer conjugates, combining the .alpha.-interferon-polymer conjugates with a sufficient amount of an acid to reduce the pH of the conjugates to a level which is sufficient to cleave the polymer linkages in an active site area of the interferon and thereafter adjusting the .alpha.-interferon-polymer conjugates to a physiologically-acceptable pH. Methods of treating interferon-susceptible conditions with the compositions of the present invention are also disclosed.Type: GrantFiled: December 19, 1997Date of Patent: November 9, 1999Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Carl W. Gilbert
-
Patent number: 5969040Abstract: Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.Type: GrantFiled: December 13, 1996Date of Patent: October 19, 1999Inventors: Terrence W. Hallahan, Carl W. Gilbert
-
Patent number: 5951974Abstract: Compositions containing alpha interferon conjugated to a substantially non-antigenic polymer are disclosed in which at least about 30% of the conjugates include covalent attachment of the alpha interferon to the substantially non-antigenic polymer at a histidine. Also disclosed is a process for preparing the conjugates. The process includes contacting an alpha interferon with a succinimidyl carbonate-activated substantially non-antigenic polymer at a pH which is sufficient to facilitate covalent attachment of the polymer on a histidine of the alpha interferon.Type: GrantFiled: December 19, 1997Date of Patent: September 14, 1999Assignee: Enzon, Inc.Inventors: Carl W. Gilbert, Myung-ok Park-Cho
-
Patent number: 5738846Abstract: Interferon-polymer conjugate containing compositions having high levels of retained interferon activity and relatively long circulating lives in vivo are disclosed. The compositions contain a mixture of mono-interferon-polymer conjugates and bis-interferon-polymer conjugates, with both species containing substantially a single polymer strand. The conjugate compositions are prepared by reacting about 1 mole of an interferon with from about 0.125 to about 1 mole of a bis-activated substantially non-antigenic polymer under conditions sufficient to effect covalent conjugation of the interferon and polymer. Methods of treating interferon-susceptible conditions with the compositions of the present invention are also disclosed.Type: GrantFiled: November 21, 1995Date of Patent: April 14, 1998Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Carl W. Gilbert
-
Patent number: 5711944Abstract: A process is disclosed for preparing long-acting alpha interferon-containing compositions. Alpha interferon is contacted with a relatively small molar excess of a substantially non-antigenic polymer in the presence of a surfactant to preserve bioactivity. Isolation of the desired conjugate species having optimal activity is also disclosed.Type: GrantFiled: November 10, 1994Date of Patent: January 27, 1998Assignee: Enzon, Inc.Inventors: Carl W. Gilbert, Myung-Ok Cho
-
Patent number: 5705153Abstract: Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have improved enzyme activity at the pH ranges associated with lysosomal, arterial and capillary regions.Type: GrantFiled: October 23, 1996Date of Patent: January 6, 1998Assignee: The United States of America, as represented by The Department of Health and Human ServicesInventors: Robert G. L. Shorr, Carl W. Gilbert, Brian M. Martin, Myung-Ok Cho, Edward J. Ginns
-
Patent number: 5650388Abstract: Polyalkylene oxide-conjugated hemoglobin solutions having a molecular weight greater than about 85,000 daltons and a degree of substitution of which substantially avoids clinically significant nephrotoxicity associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is al so disclosed.Type: GrantFiled: June 30, 1995Date of Patent: July 22, 1997Assignee: Enzon, Inc.Inventors: Robert G. L. Shorr, Carl W. Gilbert
-
Patent number: 5620884Abstract: Conjugates containing glucocerebrosidase and non-antigenic polymers such as polyethylene glycol are disclosed. The conjugates circulate for extended times and have prolonged activity in vivo when compared to unmodified enzymes. The conjugates are useful in the treatment of Gaucher's Disease and have improved enzyme activity at the pH ranges associated with lysosomal, arterial and capillary regions.Type: GrantFiled: November 30, 1994Date of Patent: April 15, 1997Assignee: Enzon, Inc.Inventors: Robert G. L. Shorr, Myung-Ok Cho, Carl W. Gilbert, Edward J. Ginns, Brian M. Martin
-
Patent number: 5621039Abstract: Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.Type: GrantFiled: June 8, 1993Date of Patent: April 15, 1997Inventors: Terrence W. Hallahan, Carl W. Gilbert
-
Patent number: 5416070Abstract: The present invention provides novel lipophilic disaccharide-dipeptide compounds. The compounds of the invention are preferably encapsulated into multilamellar liposomes, which can be formed from phosphatidyl choline and phosphatidyl glycerol. The compounds are effective in activating human monocytes with subsequent destruction of tumor cells. These compounds have acceptable toxicity in anticipated human dosages.Type: GrantFiled: April 13, 1990Date of Patent: May 16, 1995Assignee: ImmunoTherapeutics, Inc.Inventors: Gerald J. Vosika, Dennis A. Cornelius, John A. Bennek, Karl E. Swenson, Carl W. Gilbert